Quotient

Quotient EBITDA per Employee

Delisted

The EBITDA per Employee of Quotient (QTNT) as of Nov 9, 2026 is -193,154.90 USD. In the previous year, EBITDA per Employee was -187,945.33 USD — a change of 2.77% (lower).

EBITDA per Employee

-193,154.90USD

YoY

2.77%

Last updated:

EBITDA per Employee of Quotient is 2022 -193,154.90 USD. EBITDA per Employee of Quotient was 2021 -187,945.33 USD. It decreases by 2.77% lower compared to the previous year.

The Quotient EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2015
-67,685.65 USD
Jan 1, 2016
-111,817.77 USD
Jan 1, 2017
-171,220.96 USD
Jan 1, 2018
-154,036.45 USD
Jan 1, 2019
-179,851.94 USD
Jan 1, 2020
-183,806.38 USD
Jan 1, 2021
-187,945.33 USD
Jan 1, 2022
-193,154.90 USD
The Quotient EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-193,154.90USD+2.77%
-187,945.33USD+2.25%
-183,806.38USD+2.20%
-179,851.94USD+16.76%
-154,036.45USD-10.04%
-171,220.96USD+53.13%
-111,817.77USD+65.20%
-67,685.65USD+234.17%
-20,255.13USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quotient Stock analysis

What does Quotient do? Quotient Ltd is a biopharmaceutical company headquartered in Eysins, Switzerland. The company was founded in 2007 with the aim of developing innovative technologies in the field of Personalized Medicine. This means that medications and therapies are specifically tailored to the individual needs of patients. Thanks to state-of-the-art production processes, products can be produced quickly and safely. Quotient Ltd has a unique business model based on transfusion technology. This technology allows the company to produce medications quickly and accurately. The different components of the medications are separated and then combined in the required dosage. This means that the medications can be precisely dosed and the risks of side effects minimized. A key focus of Quotient Ltd is the development of therapeutics. Personalized medicine and the fast and safe production of medications are at the center of this area. The transfusion technology enables medications to be produced quickly and flexibly, which is particularly important for rare diseases and personalized therapies. Another important area is the development of diagnostics. These enable diseases to be diagnosed quickly and safely. Based on this diagnosis, suitable therapies are then developed. Quotient Ltd also relies on transfusion technology for this, which enables fast, reliable, and flexible production of diagnostics. In addition to its developed technology and know-how, Quotient Ltd also has its own production facility. Here, all products are produced to the highest standards. The production facility covers an area of approximately 6,000 square meters. The modern facility is equipped with the latest technologies and meets the highest quality standards. Quotient Ltd offers a variety of products, with a special focus on personalized medicine and the fast and safe production of medications and diagnostics. One example is the PDA diagnostic system, which was developed for the fast and accurate diagnosis of autoimmune diseases. The MosaiQ system is another important product that enables fast and reliable production of medications. The success story of Quotient Ltd is closely linked to the development of transfusion technology. The company has succeeded in developing a technology that allows for the fast and safe production of personalized medicine. This technology has made Quotient Ltd a leading company in the field of personalized medicine worldwide. Today, Quotient Ltd employs over 700 people who are constantly working on the further development of personalized medicine and transfusion technology. Quotient is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quotient stock

EBITDA per Employee of Quotient is -193,154.90 USD in 2022.

EBITDA per Employee of Quotient changed from -187,945.33 USD to -193,154.90 USD, representing a 2.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Quotient since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Quotient historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Quotient

All Key Metrics — Quotient